BlackRock’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-390,386
| Closed | -$170K | – | 5771 |
|
|
2022
Q4 | $170K | Sell |
390,386
-7
| -0% | -$2 | ﹤0.01% | 4897 |
|
|
2022
Q3 | $109K | Buy |
390,393
+7
| +0% | +$2 | ﹤0.01% | 5155 |
|
|
2022
Q2 | $141K | Sell |
390,386
-133,737
| -26% | -$55.4K | ﹤0.01% | 5129 |
|
|
2022
Q1 | $352K | Sell |
524,123
-6,552
| -1% | -$5.56K | ﹤0.01% | 4970 |
|
|
2021
Q4 | $685K | Buy |
530,675
+388,383
| +273% | +$689K | ﹤0.01% | 4781 |
|
|
2021
Q3 | $309K | Buy |
142,292
+24,583
| +21% | +$53.5K | ﹤0.01% | 4872 |
|
|
2021
Q2 | $321K | Buy |
+117,709
| New | +$293K | ﹤0.01% | 4794 |
|
|
2019
Q4 | – | Sell |
-224,555
| Closed | -$1.45M | – | 5109 |
|
|
2019
Q3 | $1.45M | Sell |
224,555
-13,335
| -6% | -$91.9K | ﹤0.01% | 3850 |
|
|
2019
Q2 | $1.48M | Buy |
237,890
+35,156
| +17% | +$268K | ﹤0.01% | 3881 |
|
|
2019
Q1 | $2.16M | Buy |
202,734
+30,900
| +18% | +$308K | ﹤0.01% | 3679 |
|
|
2018
Q4 | $1.37M | Sell |
171,834
-6,255
| -4% | -$90.2K | ﹤0.01% | 3788 |
|
|
2018
Q3 | $3.45M | Buy |
178,089
+21,240
| +14% | +$387K | ﹤0.01% | 3611 |
|
|
2018
Q2 | $2.83M | Sell |
156,849
-219,715
| -58% | -$3.24M | ﹤0.01% | 3627 |
|
|
2018
Q1 | $4.01M | Buy |
376,564
+12,537
| +3% | +$201K | ﹤0.01% | 3486 |
|
|
2017
Q4 | $15.3M | Buy |
364,027
+181,806
| +100% | +$8.16M | ﹤0.01% | 2914 |
|
|
2017
Q3 | $10M | Buy |
182,221
+19,650
| +12% | +$3.31M | ﹤0.01% | 3174 |
|
|
2017
Q2 | $30.2M | Buy |
162,571
+28,957
| +22% | +$5.08M | ﹤0.01% | 2545 |
|
|
2017
Q1 | $16M | Buy |
133,614
+133,271
| +38,855% | +$14M | ﹤0.01% | 2881 |
|
|
2016
Q4 | $34K | Sell |
343
-3,863
| -92% | -$407K | ﹤0.01% | 3096 |
|
|
2016
Q3 | $472K | Sell |
4,206
-283
| -6% | -$34K | ﹤0.01% | 1767 |
|
|
2016
Q2 | $461K | Sell |
4,489
-93
| -2% | -$9.3K | ﹤0.01% | 1704 |
|
|
2016
Q1 | $421K | Buy |
4,582
+207
| +5% | +$22.1K | ﹤0.01% | 1592 |
|
|
2015
Q4 | $631K | Sell |
4,375
-738
| -14% | -$96K | ﹤0.01% | 1472 |
|
|
2015
Q3 | $528K | Hold |
5,113
| – | – | ﹤0.01% | 1497 |
|
|
2015
Q2 | $834K | Buy |
+5,113
| New | +$867K | ﹤0.01% | 1426 |
|
Other funds holding SIOX
JC
CIA
BBA
BlackRock's SIOX Position: Q1 2023 in Review
BlackRock sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 390,386 shares — an estimated $170K sold.
BlackRock first reported a position in SIOX in Q2 2015 and held it in 25 quarters. The position peaked at $30.2M in Q2 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.
- BlackRock reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- BlackRock sold 390,386 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $170K.
- BlackRock first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 25 quarters.
- BlackRock's Sio Gene Therapies Inc. Common Stock position peaked at $30.2M in Q2 2017.
- 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.
Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.